Premature birth with neonatal acute kidney failure due to intrauterine exposure of sacubitril valsartan in the third trimester of pregnancy
10.3760/cma.j.cn114015-20230313-00184
- VernacularTitle:孕晚期沙库巴曲缬沙坦暴露致新生儿早产合并急性肾衰竭
- Author:
Zhihui MA
1
;
Ligang JI
1
;
Minmin ZHAO
1
Author Information
1. 山西省晋城大医院药学部，晋城 048006
- Publication Type:Journal Article
- Keywords:
Pregnancy;
Maternal exposure;
Sacubitril valsartan;
Premature birth;
Acute kidney failure
- From:
Adverse Drug Reactions Journal
2023;25(12):759-760
- CountryChina
- Language:Chinese
-
Abstract:
A preterm male infant suffered from continuous anuria for 20 hours, with systemic edema, serum creatinine 238 μmol/L, creatinine clearance rate 19.45 ml/min, cystatin C 5.05 mg/L, serum albumin 28.8 g/L, β 2 microglobulin 6.52 mg/L, and urinary microalbumin 120.2 mg/L. He was diagnosed with acute kidney failure and hypoalbuminemia. Before his birth, his mother had been treated with sacubitril valsartan sodium tablets (50 mg, twice daily), bumetanide tablets (1 mg, once daily), clopidogrel hydrogen sulfate tablets (75 mg, once daily) and pitavastatin calcium tablets (2 mg, once daily) for 9 days due to misdiagnose. The acute kidney failure and hypoalbuminemia was considered to be associated with in utero exposure to sacubitril valsartan in the third trimester, and symptomatic and supportive treatments such as intravenous albumin supplementation, furosemide, and dopamine were given. After 56 hours of birth, his urine volume obviously increased; after 5 days, his urine volume returned to normal; after 8 days, his renal function basically returned to normal.
